Id | Content |
---|---|
F1 | The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. |
F2 | The options vest as follows: 25% on each of October 31, 2024; January 31, 2025; April 30, 2025; and July 31, 2025. |
F3 | Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested. |
F4 | The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis. |